These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32431020)

  • 21. Tadalafil 5 mg once daily for the treatment of erectile dysfunction during a 6-month observational study (EDATE): impact of patient characteristics and comorbidities.
    Hatzichristou D; d'Anzeo G; Porst H; Buvat J; Henneges C; Rossi A; Hamidi K; Büttner H
    BMC Urol; 2015 Nov; 15():111. PubMed ID: 26563171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erectile dysfunction in patients taking psychotropic drugs and treated with phosphodiesterase-5 inhibitors.
    Mazzilli R; Angeletti G; Olana S; Delfino M; Zamponi V; Rapinesi C; Del Casale A; Kotzalidis GD; Elia J; Callovini G; Girardi P; Mazzilli F
    Arch Ital Urol Androl; 2018 Mar; 90(1):44-48. PubMed ID: 29633797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Couples' reasons for adherence to, or discontinuation of, PDE type 5 inhibitors for men with erectile dysfunction at 12 to 24-month follow-up after a 6-month free trial.
    Conaglen HM; Conaglen JV
    J Sex Med; 2012 Mar; 9(3):857-65. PubMed ID: 22239731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment effects of phosphodiesterase-5 inhibitors may improve with time following nerve-sparing radical prostatectomy.
    Fode M; Østergren PB; Jensen CFS; Jakobsen H; Sønksen J
    Scand J Urol; 2018 Apr; 52(2):108-110. PubMed ID: 29057723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis.
    Yan H; Zong H; Cui Y; Li N; Zhang Y
    J Sex Med; 2014 Jun; 11(6):1539-45. PubMed ID: 24621088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of erectile dysfunction course on its progress and efficacy of treatment with phosphodiesterase type 5 inhibitors.
    Liu DF; Jiang H; Hong K; Zhao LM; Tang WH; Ma LL
    Chin Med J (Engl); 2010 Nov; 123(22):3258-61. PubMed ID: 21163126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Undertreatment of erectile dysfunction: claims analysis of 6.2 million patients.
    Frederick LR; Cakir OO; Arora H; Helfand BT; McVary KT
    J Sex Med; 2014 Oct; 11(10):2546-53. PubMed ID: 25059314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized, double-blind, placebo-controlled, parallel study to assess the efficacy and safety of once-a-day tadalafil in men with erectile dysfunction who are naïve to PDE5 inhibitors.
    Montorsi F; Aversa A; Moncada I; Perimenis P; Porst H; Barker C; Shane MA; Sorsaburu S
    J Sex Med; 2011 Sep; 8(9):2617-24. PubMed ID: 21707928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lessons learnt from the variation across 6741 family/general practices in England in the use of treatments for hypogonadism.
    Heald AH; Stedman M; Whyte M; Livingston M; Albanese M; Ramachandran S; Hackett G
    Clin Endocrinol (Oxf); 2021 May; 94(5):827-836. PubMed ID: 33420743
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sexual Dysfunction in Type 2 Diabetes at Diagnosis: Progression over Time and Drug and Non-Drug Correlated Factors.
    Corona G; Giorda CB; Cucinotta D; Guida P; Nada E;
    PLoS One; 2016; 11(10):e0157915. PubMed ID: 27706160
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [PDE5: A new therapeutic target for lower urinary tract symptoms/ benign prostatic hyperplasia combined with erectile dysfunction].
    Xu Z; Jia RP
    Zhonghua Nan Ke Xue; 2018 Apr; 24(4):355-359. PubMed ID: 30168958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A 6-month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Middle Eastern and North African men with erectile dysfunction.
    El-Meliegy A; Rabah D; Al-Mitwalli K; Mostafa T; Hussein T; Istarabadi M; Lei Y; Gurbuz S
    Curr Med Res Opin; 2013 Jun; 29(6):707-17. PubMed ID: 23540436
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patients responding to phosphodiesterase type 5 inhibitor therapy: what do their sexual partners know?
    Klotz T; Mathers M; Klotz R; Sommer F
    J Sex Med; 2007 Jan; 4(1):162-165. PubMed ID: 17087808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient characteristics and treatment patterns for patients with benign prostatic hyperplasia, erectile dysfunction or co-occurring benign prostatic hyperplasia and erectile dysfunction in general practices in the UK: a retrospective observational study.
    Ilo D; Raluy-Callado M; Graham-Clarke P; Sadasivan R; Birt J; Donaldson R; Zhu E; Kirby MG; Neasham D
    Int J Clin Pract; 2015 Aug; 69(8):853-62. PubMed ID: 26011100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A 6 month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Latin American men with erectile dysfunction.
    Rubio-Aurioles E; Reyes LA; Borregales L; Cairoli C; Sorsaburu S
    Curr Med Res Opin; 2013 Jun; 29(6):695-706. PubMed ID: 23540375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of psychological intervention and phosphodiesterase-5 inhibitors for erectile dysfunction: a narrative review and meta-analysis.
    Schmidt HM; Munder T; Gerger H; Frühauf S; Barth J
    J Sex Med; 2014 Jun; 11(6):1376-91. PubMed ID: 24641632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pattern of prescribing of glucose modulating agents for type 2 diabetes in general practices in England 2016/17.
    Heald AH; Livingston M; Bien Z; Moreno GYC; Laing I; Stedman M
    Int J Clin Pract; 2018 Apr; 72(4):e13080. PubMed ID: 29537664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of phosphodiesterase type 5 (PDE5) inhibitors in treating erectile dysfunction after bilateral nerve-sparing radical prostatectomy.
    Cui Y; Liu X; Shi L; Gao Z
    Andrologia; 2016 Feb; 48(1):20-8. PubMed ID: 25684196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Erectile dysfunction and cardiovascular disease.
    Menezes A; Artham S; Lavie CJ; Milani RV; O'Keefe J
    Postgrad Med; 2011 May; 123(3):7-16. PubMed ID: 21566411
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer.
    Lian Y; Yin H; Pollak MN; Carrier S; Platt RW; Suissa S; Azoulay L
    Eur Urol; 2016 Nov; 70(5):808-815. PubMed ID: 27178449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.